Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplants Events

The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant

Abstract

In this multicenter study, we assessed the use of palifermin (recombinant human–keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 μg/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1–4 (58 vs 94%, P<0.001), 3–4 (13 vs 43%, P<0.001) and the median duration of OM (4 vs 9 days, P<0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%, P<0.001), opioid analgesics (24 vs 64%, P<0.001) and total parenteral nutrition (11 vs 45%, P<0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (P=0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pico JL, Avila-Garavito A, Naccache P . Mucositis: its occurrence, consequences and treatment in the oncology setting. Oncologist 1998; 3: 446–461.

    CAS  PubMed  Google Scholar 

  2. Plevova P . Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis: a review. Oral Oncol 1999; 35: 453–470.

    Article  CAS  PubMed  Google Scholar 

  3. Epstein JB, Schubert MM . Oropharyngeal mucositis in cancer therapy—review of pathogenesis, diagnosis and management. Oncology 2003; 17: 1767–1779.

    PubMed  Google Scholar 

  4. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM . Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 2004; 22: 1268–1275.

    Article  PubMed  Google Scholar 

  5. Rapoport AP, Miller Watelet LE, Linder T, Eberly S, Raubertas RF, Lipp J et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem cell transplants. J Clin Oncol 1999; 17: 2446–2453.

    Article  CAS  PubMed  Google Scholar 

  6. Sonis S, Oster G, Fuchs H, Bellm L, Bradford Z, Edelsberg J et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 2001; 19: 2201–2205.

    Article  CAS  PubMed  Google Scholar 

  7. Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest 2002; 20: 793–800.

    Article  PubMed  Google Scholar 

  8. Hofmeister CC, Stiff PJ . Mucosal protection by cytokines. Curr Hematol Rep 2005; 4: 446–453.

    CAS  PubMed  Google Scholar 

  9. Peterson DE . New strategies for management of oral mucositis in cancer patients. J Support Oncol 2006; 4: 9–13.

    CAS  PubMed  Google Scholar 

  10. Von Bultzingslowen I, Brennan MT, Spijkervet FK, Logan R, Stringer A, Raber-Durlacher JE et al. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis. Support Care Cancer 2006; 14: 519–527.

    Article  PubMed  Google Scholar 

  11. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA . Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA 1989; 86: 802–806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Danilenko DM . Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 1999; 27: 64–71.

    Article  CAS  PubMed  Google Scholar 

  13. Borges L, Rex KL, Chen JN, Wei P, Kaufman S, Scully S et al. A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy induced mucositis. Int J Radiat Oncol Biol Phys 2006; 66: 254–262.

    Article  CAS  PubMed  Google Scholar 

  14. Werner S . Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev 1998; 9: 153–165.

    Article  CAS  PubMed  Google Scholar 

  15. Blijlevens N, Sonis S . Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy and radiotherapy induced mucositis. Ann Oncol 2007; 18: 817–826.

    Article  CAS  PubMed  Google Scholar 

  16. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  CAS  PubMed  Google Scholar 

  17. Przepiorka D, Weisdorf D, Martin P, Culbert SJ, Petropoulos D, Ippoliti C et al. 1994 Consensus conference on acute GvHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  18. Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 2006; 37: 393–401.

    Article  CAS  PubMed  Google Scholar 

  19. Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S et al. A phase I/II randomized, placebo–control trial of Palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216–3221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 10–18.

    Article  Google Scholar 

  21. Radtke ML, Kolesar JM . Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract 2005; 11: 121–125.

    Article  CAS  PubMed  Google Scholar 

  22. Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J . Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 2007; 15: 105–109.

    Article  PubMed  Google Scholar 

  23. Hueber AJ, Leipe J, Roesler W, Kalden JR, Kallert S, Rech J . Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis. Haematologica 2006; 91 (Suppl 8): 32.

    Google Scholar 

  24. Langner S, Staber P, Radspieler G, Triebl-Roth K, Urban C, Zinke-Cerwenka W et al. Palifermin reduces oral mucositis and enhances the recovery of intestinal mucosa measured by citrulline serum levels in allogeneic and autologous stem cell transplant recipients. Bone Marrow Transplant 2006; 37: S73.

    Article  Google Scholar 

  25. Vanclee A, Lutgens LC, Oving EB, Deutz NE, Gijbels MJ, Schouten HC et al. Keratinocyte growth factor ameliorates acute graft versus host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant 2005; 36: 907–915.

    Article  CAS  PubMed  Google Scholar 

  26. Ellison CA, Gibson IW, Hayglass KT, Gartner JG . Effect of palifermin in a murine model of graft versus host disease (GvHD) associated with th2 cytokine production, autoantibody production and glomerulonephritis. J Clin Immunol 2006; 26: 485–494.

    Article  CAS  PubMed  Google Scholar 

  27. Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ, Smogorzewska M et al. Factors affecting thymic recovery after allogeneic hematopoietic stem cell transplantation. Blood 2001; 97: 1458–1466.

    Article  CAS  PubMed  Google Scholar 

  28. Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, van den Brink MRM et al. Direct evidence for new T-cell generation by patients after either T-cell depleted or unmodified allogeneic hematopoietic stem cell transplantation. Blood 2002; 100: 2235–2242.

    CAS  PubMed  Google Scholar 

  29. Finch PW, Rubin JS . Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst 2006; 98: 812–824.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B Nasilowska-Adamska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nasilowska-Adamska, B., Rzepecki, P., Manko, J. et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 40, 983–988 (2007). https://doi.org/10.1038/sj.bmt.1705846

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705846

Keywords

This article is cited by

Search

Quick links